EP3068394A4 - Formes solides d'acide {[5-(3-chlorophényl)-3-hydroxypyridine-2-carbonyl]amino}acétique, compositions et leurs utilisations - Google Patents

Formes solides d'acide {[5-(3-chlorophényl)-3-hydroxypyridine-2-carbonyl]amino}acétique, compositions et leurs utilisations Download PDF

Info

Publication number
EP3068394A4
EP3068394A4 EP14861394.6A EP14861394A EP3068394A4 EP 3068394 A4 EP3068394 A4 EP 3068394A4 EP 14861394 A EP14861394 A EP 14861394A EP 3068394 A4 EP3068394 A4 EP 3068394A4
Authority
EP
European Patent Office
Prior art keywords
hydroxypyridine
chlorophenyl
carbonyl
amino
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP14861394.6A
Other languages
German (de)
English (en)
Other versions
EP3068394A1 (fr
Inventor
James Densmore Copp
Ann W. Newman
Anne Luong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Akebia Therapeutics Inc
Original Assignee
Akebia Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akebia Therapeutics Inc filed Critical Akebia Therapeutics Inc
Priority to EP19172252.9A priority Critical patent/EP3578546A1/fr
Publication of EP3068394A1 publication Critical patent/EP3068394A1/fr
Publication of EP3068394A4 publication Critical patent/EP3068394A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/803—Processes of preparation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicinal Preparation (AREA)
EP14861394.6A 2013-11-15 2014-11-14 Formes solides d'acide {[5-(3-chlorophényl)-3-hydroxypyridine-2-carbonyl]amino}acétique, compositions et leurs utilisations Withdrawn EP3068394A4 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP19172252.9A EP3578546A1 (fr) 2013-11-15 2014-11-14 Formes solides d'acide acétique {[5-(3-chlorophényl) -3-hydroxypyridine-2-carbonyl] amino}, compositions et leurs utilisations

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361904803P 2013-11-15 2013-11-15
PCT/US2014/065631 WO2015073779A1 (fr) 2013-11-15 2014-11-14 Formes solides d'acide {[5-(3-chlorophényl)-3-hydroxypyridine-2-carbonyl] amino}acétique, compositions et leurs utilisations

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP19172252.9A Division EP3578546A1 (fr) 2013-11-15 2014-11-14 Formes solides d'acide acétique {[5-(3-chlorophényl) -3-hydroxypyridine-2-carbonyl] amino}, compositions et leurs utilisations

Publications (2)

Publication Number Publication Date
EP3068394A1 EP3068394A1 (fr) 2016-09-21
EP3068394A4 true EP3068394A4 (fr) 2017-04-26

Family

ID=53058045

Family Applications (2)

Application Number Title Priority Date Filing Date
EP14861394.6A Withdrawn EP3068394A4 (fr) 2013-11-15 2014-11-14 Formes solides d'acide {[5-(3-chlorophényl)-3-hydroxypyridine-2-carbonyl]amino}acétique, compositions et leurs utilisations
EP19172252.9A Pending EP3578546A1 (fr) 2013-11-15 2014-11-14 Formes solides d'acide acétique {[5-(3-chlorophényl) -3-hydroxypyridine-2-carbonyl] amino}, compositions et leurs utilisations

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP19172252.9A Pending EP3578546A1 (fr) 2013-11-15 2014-11-14 Formes solides d'acide acétique {[5-(3-chlorophényl) -3-hydroxypyridine-2-carbonyl] amino}, compositions et leurs utilisations

Country Status (24)

Country Link
US (7) US9701636B2 (fr)
EP (2) EP3068394A4 (fr)
JP (5) JP2016537365A (fr)
KR (2) KR102495018B1 (fr)
CN (2) CN105916502A (fr)
AR (2) AR099354A1 (fr)
AU (4) AU2014348523B2 (fr)
BR (1) BR112016011065B1 (fr)
CA (1) CA2930128A1 (fr)
CL (1) CL2016001150A1 (fr)
CR (2) CR20160222U (fr)
DO (1) DOP2016000109A (fr)
IL (2) IL245634A0 (fr)
MA (1) MA39033A1 (fr)
MX (3) MX2021001169A (fr)
MY (1) MY180626A (fr)
PE (1) PE20160945A1 (fr)
PH (2) PH12021551124A1 (fr)
RU (2) RU2016123382A (fr)
SA (1) SA516371129B1 (fr)
SG (2) SG10201803862UA (fr)
TW (5) TW201946625A (fr)
WO (1) WO2015073779A1 (fr)
ZA (3) ZA201603189B (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0713350B1 (pt) 2006-06-26 2022-04-12 Akebia Therapeutics Inc Composto, e, composição
NO2686520T3 (fr) 2011-06-06 2018-03-17
SG10201910773VA (en) 2013-06-13 2020-01-30 Akebia Therapeutics Inc Compositions and methods for treating anemia
AR099354A1 (es) 2013-11-15 2016-07-20 Akebia Therapeutics Inc Formas sólidas de ácido {[5-(3-clorofenil)-3-hidroxipiridin-2-carbonil]amino}acético, composiciones, y sus usos
WO2015112831A1 (fr) * 2014-01-23 2015-07-30 Akebia Therapeutics, Inc. Compositions et méthodes de traitement de maladies oculaires
AU2016209126A1 (en) 2015-01-23 2017-08-10 Akebia Therapeutics, Inc. Solid forms of 2-(5-(3-fluorophenyl)-3-hydroxypicolinamido)acetic acid, compositions, and uses thereof
US11324734B2 (en) 2015-04-01 2022-05-10 Akebia Therapeutics, Inc. Compositions and methods for treating anemia
CN105837502A (zh) * 2016-04-05 2016-08-10 湖南欧亚生物有限公司 一种Vadadustat的合成方法
MX2019006883A (es) * 2016-12-13 2019-10-21 Crystal Pharmaceutical Suzhou Co Ltd Formas cristalinas novedosas de ácido {[5-(3-clorofenil)-3-idroxip iridina-2-carbonilo] amino} acético y procedimientos para la preparación del mismo.
WO2019028150A1 (fr) * 2017-08-01 2019-02-07 Akebia Therapeutics, Inc. Compositions destinées à être utilisées dans des méthodes de traitement des hémoglobinopathies
EP3790863A1 (fr) 2018-05-09 2021-03-17 Akebia Therapeutics Inc. Procédé de préparation d'acide 2-[[5-(3-chlorophényl)-3-hydroxypyridine-2-carbonyl] amino]acétique
WO2020075199A1 (fr) 2018-10-12 2020-04-16 Mylan Laboratories Limited Formes polymorphes de vadadustat
WO2020108941A1 (fr) 2018-11-28 2020-06-04 Sandoz Ag Cristaux à plusieurs composants d'un inhibiteur de hif prolyl hydroxylase disponible par voie orale
US11524939B2 (en) 2019-11-13 2022-12-13 Akebia Therapeutics, Inc. Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid
IT202000014116A1 (it) * 2020-06-12 2021-12-12 Olon Spa Nuovo composto cristallino di vadadustat
CN111825606A (zh) * 2020-06-17 2020-10-27 上海希迈医药科技有限公司 一种伐度司他晶型及其制备方法
KR20230027157A (ko) * 2020-06-19 2023-02-27 아케비아 테라퓨틱스 인코포레이티드 바다두스타트의 약물-약물 상호작용의 조절
GB202011431D0 (en) * 2020-07-23 2020-09-09 Johnson Matthey Plc Polymorphs of vadadustat and methods for preparing the polymorphs
CN114105866A (zh) * 2020-08-26 2022-03-01 广东东阳光药业有限公司 一种低氧诱导因子脯氨酰羟化酶抑制剂的晶型及其制备方法
CN115996720A (zh) * 2020-09-04 2023-04-21 广东东阳光药业有限公司 一种低氧诱导因子脯氨酰羟化酶抑制剂的晶型及其制备方法
WO2022150621A1 (fr) 2021-01-08 2022-07-14 Akebia Therapeutics, Inc. Méthodes thérapeutiques utilisant du vadadustat
WO2022179967A1 (fr) 2021-02-23 2022-09-01 Glaxosmithkline Intellectual Property (No.2) Limited Vadadustat pour le traitement de la covid-19 chez un sujet hospitalisé
EP4301352A1 (fr) * 2021-03-01 2024-01-10 Akebia Therapeutics Inc. Modulation d?interactions médicamenteuses du vadadustat

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120309977A1 (en) * 2011-06-06 2012-12-06 Akebia Therapeutics Inc. Process for preparing [(3-hydroxypyridine-2-carbonyl)amino]alkanoic acids, esters and amides
US20130203816A1 (en) * 2006-06-26 2013-08-08 Akebia Therapeutics Inc. Prolyl hydroxylase inhibitors and methods of use

Family Cites Families (195)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3894920A (en) 1971-12-21 1975-07-15 Sagami Chem Res Process for preparing alkyl-substituted 3,6-dihydro-o-dioxin derivatives
US4016287A (en) 1972-07-17 1977-04-05 Boehringer Ingelheim Gmbh Dermatological compositions containing an acylamino-carboxylic acid or an alkyl ester thereof
WO1990000882A1 (fr) 1988-07-25 1990-02-08 Vsesojuzny Kurgansky Nauchny Tsentr 'vosstanovitelnaya Travmatologia I Ortopedia' Appareil de traction servant a retablir la forme de la main
TW219933B (fr) 1990-02-26 1994-02-01 Lilly Co Eli
US5405613A (en) 1991-12-11 1995-04-11 Creative Nutrition Canada Corp. Vitamin/mineral composition
TW352384B (en) 1992-03-24 1999-02-11 Hoechst Ag Sulfonamido- or sulfonamidocarbonylpyridine-2-carboxamides, process for their preparation and their use as pharmaceuticals
DE4219158A1 (de) 1992-06-11 1993-12-16 Thomae Gmbh Dr K Biphenylderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
ES2101420T3 (es) 1993-11-02 1997-07-01 Hoechst Ag Esteres-amidas de acidos carboxilicos heterociclicos sustituidos, su preparacion y su utilizacion como medicamentos.
EP0650961B1 (fr) 1993-11-02 1997-03-05 Hoechst Aktiengesellschaft Amides d'acide carboxylique hétérocycliques substitués, leur preparation et leur utilisation comme médicaments
NZ270267A (en) 1993-12-30 1997-03-24 Hoechst Ag 3-hydroxypyridin-2yl (and -quinolin-2-yl) carboxamide derivatives and pharmaceutical compositions
DE4410480A1 (de) 1994-03-25 1995-09-28 Hoechst Ag Sulfonamidocarbonylpyridin-2-carbonsäureesteramide sowie ihre Pyridin-N-oxide, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE4410423A1 (de) 1994-03-25 1995-09-28 Hoechst Ag Sulfonamidocarbonylpyridin-2-carbonsäureamide sowie ihre Pyridin-N-oxide, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
IL135495A (en) 1995-09-28 2002-12-01 Hoechst Ag Intermediate compounds for the preparation of quinoline-converted amines - 2 - carboxylic acid
JPH09221476A (ja) 1995-12-15 1997-08-26 Otsuka Pharmaceut Co Ltd 医薬組成物
WO1997041103A1 (fr) 1996-04-30 1997-11-06 Hoechst Aktiengesellschaft Esters d'amide de 3-alcoxypyridine-2-acide carboxylique, leur preparation et leur utilisation comme medicaments
DE19620041A1 (de) 1996-05-17 1998-01-29 Merck Patent Gmbh Adhäsionsrezeptor-Antagonisten
DE19650215A1 (de) 1996-12-04 1998-06-10 Hoechst Ag 3-Hydroxypyridin-2-carbonsäureamidester, ihre Herstellung und ihre Verwendung als Arzneimittel
EP1024134A4 (fr) 1997-10-09 2003-05-14 Ono Pharmaceutical Co Derives d'acide aminobutanoique
DE19746287A1 (de) 1997-10-20 1999-04-22 Hoechst Marion Roussel De Gmbh Substituierte Isochinolin-2-Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
ATE273277T1 (de) 1998-03-23 2004-08-15 Aventis Pharma Inc Piperidinyl- und n-amidinopiperidinyl-derivate
IL141423A (en) 1998-08-27 2005-09-25 Teva Pharma Hydrate forms of alendronate sodium, processes for manufacture thereof, and pharmaceutical compositions thereof
US6500987B1 (en) 1998-11-27 2002-12-31 Teva Pharmaceutical Industries Ltd. Sertraline hydrochloride polymorphs
HK1040979A1 (zh) 1998-11-27 2002-06-28 Teva Pharmaceutical Industries Ltd. 盐酸舍曲林多晶型物
US6159379A (en) 1999-05-04 2000-12-12 Baker Hughes Incorporated Organic ammonium salts for the removal of water soluble organics in produced water
JP2001048786A (ja) 1999-08-05 2001-02-20 Yamanouchi Pharmaceut Co Ltd 三環式ヘテロアリール誘導体
CN1378448A (zh) 1999-08-11 2002-11-06 特瓦制药工业有限公司 多晶型托拉塞米
EP2206497A1 (fr) 1999-11-17 2010-07-14 Teva Pharmaceutical Industries Ltd. Form polymorphe de atorvastatin calcium
SK8312002A3 (en) 1999-12-14 2003-05-02 Biogal Gyogyszergyar Novel forms of pravastatin sodium
CN1411373A (zh) 1999-12-16 2003-04-16 特瓦制药工业有限公司 制备来氟米特的新方法和新晶形的来氟米特
AU783055B2 (en) 1999-12-16 2005-09-22 Teva Pharmaceutical Industries Ltd. Processes for preparing clarithromycin polymorphs and novel polymorph IV
ES2281374T3 (es) 1999-12-21 2007-10-01 Teva Pharmaceutical Industries Ltd. Nuevos polimorfos de hidrocloruro de sertralina, procedimientos para su preparacion, composiciones que los contienen y metodos para su utilizacion.
WO2001051919A2 (fr) 2000-01-07 2001-07-19 Transform Pharmaceuticals, Inc. Formation, identification et analyse a productivites elevees de formes solides diverses
RU2002118308A (ru) 2000-01-11 2004-02-20 Тева Фамэситикл Индастрис Лтд. (Il) Способы получения полиморфных модификаций кларитромицина
US6589758B1 (en) 2000-05-19 2003-07-08 Amgen Inc. Crystal of a kinase-ligand complex and methods of use
CZ2003529A3 (cs) 2000-07-27 2003-09-17 Teva Pharmaceutical Industries Ltd. Krystalický a čistý modafinil a postup jeho přípravy
US20020183553A1 (en) 2000-10-19 2002-12-05 Ben-Zion Dolitzky Crystalline venlafaxine base and novel polymorphs of venlafaxine hydrochloride, processes for preparing thereof
SK5762003A3 (en) 2000-10-19 2003-11-04 Teva Pharma Crystalline venlafaxine base and novel polymorphs of venlafaxine hydrochloride, processes for preparing thereof
EP1339707A2 (fr) 2000-10-30 2003-09-03 Teva Pharmaceutical Industries Ltd. Nouvelles formes de cristaux et solvates de chlorhydrate d'ondansetron et leurs procedes de preparation
EP1332130A4 (fr) 2000-11-03 2004-01-21 Teva Pharma Atorvastatine hemicalcique forme vii
IL156055A0 (en) 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
US7501450B2 (en) 2000-11-30 2009-03-10 Teva Pharaceutical Industries Ltd. Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
JP2004526706A (ja) 2001-02-12 2004-09-02 テバ ファーマシューティカル インダストリーズ リミティド オクスカルバゼピンの新しい結晶形態及びそれらの調製方法
US6849718B2 (en) 2001-03-20 2005-02-01 Dana Farber Cancer Institute, Inc. Muteins of hypoxia inducible factor alpha and methods of use thereof
US6855510B2 (en) 2001-03-20 2005-02-15 Dana Farber Cancer Institute, Inc. Pharmaceuticals and methods for treating hypoxia and screening methods therefor
JP4590157B2 (ja) 2001-03-21 2010-12-01 アイシス イノヴェイション リミテッド アッセイ、方法および手段
CZ20033019A3 (cs) 2001-04-09 2004-07-14 Teva Pharmaceutical Industries Ltd. Polymorfní formy chloridu fexofenadinu
SE0101327D0 (sv) 2001-04-12 2001-04-12 Astrazeneca Ab New crystalline forms
IL160076A0 (en) 2001-08-01 2004-06-20 Biogal Gyogyszergyar Process for purifying n-[3-(3-cyanopyrazolo{1,5-a} pyrimidin-7-yl) phenyl]-n-ethylacetamide (zaleplon) and crystalline forms of zaleplon accessible with the process
CZ2004446A3 (cs) 2001-09-07 2005-01-12 Teva Pharmaceutical Industries Ltd. Krystalické formy valaciklovir hydrochloridu
WO2003028664A2 (fr) 2001-10-03 2003-04-10 Teva Pharmaceutical Industries Ltd. Préparation de lévofloxacine et formes à base de cette substance
US6566088B1 (en) 2001-10-04 2003-05-20 Board Of Regents, The University Of Texas System Prolyl-4-hydroxylases
GB0124941D0 (en) 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
AU2002357701A1 (en) 2001-11-08 2003-05-19 Teva Pharmaceutical Industries Ltd. Polymorphs of fexofenadine base
MXPA04004657A (es) 2001-11-14 2004-08-13 Teva Pharma Formas amorfas y cristalinas de potasio de losartan y proceso para su preparacion.
EP1470116A4 (fr) 2001-12-04 2005-04-06 Biogal Gyogyszergyar Preparation de l'orlistat et de formes cristallines de l'orlistat
CN102552263A (zh) 2001-12-06 2012-07-11 法布罗根股份有限公司 提高内源性红细胞生成素(epo)的方法
JP2005514387A (ja) 2001-12-18 2005-05-19 テバ ファーマシューティカル インダストリーズ リミティド クロピドグレル硫酸水素塩の多型体
PL371263A1 (en) 2001-12-28 2005-06-13 Biogal Gyogyszergyar Rt Processes for preparing crystalline and amorphous mupirocin calcium
KR20040077872A (ko) 2002-01-15 2004-09-07 테바 파마슈티컬 인더스트리즈 리미티드 카베디롤의 결정질 고체 및 그 제조 방법
CN100406436C (zh) 2002-02-15 2008-07-30 特瓦制药工业有限公司 阿托韦兹他汀半钙结晶以及制备阿托韦兹他汀半钙形式ix的方法
AU2003235435A1 (en) 2002-03-20 2003-10-08 Teva Pharmaceutical Industries Ltd. Crystalline forms of quetiapine hemifumarate
PL373539A1 (en) 2002-03-27 2005-09-05 Teva Pharmaceutical Industries Ltd. Lansoprazole polymorphs and processes for preparation thereof
US20030195170A1 (en) 2002-04-11 2003-10-16 Judith Aronhime Novel polymorphs and pseudopolymorphs of risedronate sodium
AU2003251290A1 (en) 2002-04-29 2003-11-17 Teva Pharmaceutical Industries Ltd. Process for preparation of polymorphic form ii of sertraline hydrochloride, pharmaceutical formulations and methods of administration thereof
MXPA04010845A (es) 2002-04-30 2005-01-25 Biogal Gyogyszergyar Formas cristalinas novedosas de ondansetron, procesos para su preparacion, composiciones farmaceuticas que contienen las formas novedosas y metodos para tratar las nauseas utilizando las mismas.
WO2003094919A2 (fr) 2002-05-10 2003-11-20 Teva Pharmaceutical Industries Ltd. Nouvelles formes cristallines de gatifloxacine
ES2239554T1 (es) 2002-06-10 2005-10-01 Teva Pharmaceutical Industries Ltd. Forma xvi polimorfica de hidrocloruro de fexofenadina.
EP1471911A1 (fr) 2002-06-14 2004-11-03 Teva Pharmaceutical Industries Ltd. Formes cristallines de gatifloxacine
EP1467964A1 (fr) 2002-07-18 2004-10-20 Teva Pharmaceutical Industries Limited Formes polymorphes de nateglinide
US7534913B2 (en) 2002-07-18 2009-05-19 Teva Pharmaceutica Industries Ltd. Crystalline form of nateglinide
US20040022764A1 (en) * 2002-07-31 2004-02-05 Hanan Polansky Inhibition of microcompetition with a foreign polynucleotide as treatment of chronic disease
PL374993A1 (en) 2002-08-06 2005-11-14 Teva Pharmaceutical Industries Ltd. Novel crystalline forms of gatifloxacin
AU2003268213A1 (en) 2002-08-26 2004-03-11 Teva Pharmaceutical Industries Ltd. Crystalline solid famciclovir forms i, ii, iii and preparation thereof
US20050043329A1 (en) 2002-09-06 2005-02-24 Shlomit Wizel Crystalline forms of valacyclovir hydrochloride
CA2508871C (fr) 2002-11-28 2008-09-09 Teva Pharmaceutical Industries Ltd. Forme cristalline f de sel d'hemi-calcium d'astorvastatine
US7618940B2 (en) 2002-12-06 2009-11-17 Fibrogen, Inc. Fat regulation
US8124582B2 (en) 2002-12-06 2012-02-28 Fibrogen, Inc. Treatment of diabetes
CA2510625A1 (fr) 2002-12-12 2004-07-01 Teva Pharmaceutical Industries Ltd. Formes cristallines de gatifloxacine et procedes de preparation associes
US7323459B2 (en) 2002-12-24 2008-01-29 Teva Pharmaceutical Industries Ltd. Crystal forms, methods for their preparation and method for preparation of olanzapine
WO2004080461A2 (fr) 2003-03-12 2004-09-23 TEVA Gyógyszergyár Részvénytársaság Compositions pharmaceutiques stables de desloratadine
WO2004080961A2 (fr) 2003-03-12 2004-09-23 Teva Pharmaceutical Industries Ltd. Formes solides cristallines et amorphes de pantoprazole et procedes de preparation de ces formes
ES2238022T3 (es) 2003-03-17 2008-11-01 Teva Pharmaceutical Industries Ltd. Poliformos de valsartan.
US7645876B2 (en) 2004-12-01 2010-01-12 TEVA Gyógyszergyár Zártkörúen Müködö Részvénytársaság Processes for producing crystalline macrolides
US7452991B2 (en) 2003-05-15 2008-11-18 Teva Gyógyszergyár Zártkörüen Müködö Részvénytársaság Aztreonam β polymorph with very low residual solvent content
TW200510414A (en) 2003-06-02 2005-03-16 Teva Pharma Novel crystalline forms of valacyclovir hydrochloride
WO2005016325A2 (fr) 2003-06-03 2005-02-24 Teva Pharmaceutical Industries Ltd. Chlorhydrate de ziprasidone cristallin et ses procedes de preparation
CA2528232C (fr) 2003-06-06 2010-05-25 Fibrogen, Inc. Nouveaux composes heteroaryles contenant de l'azote et leur utilisation pour augmenter l'erythropoietine endogene
US7368468B2 (en) 2003-06-18 2008-05-06 Teva Pharmaceutical Industries Ltd. Fluvastatin sodium crystal forms XIV, LXXIII, LXXIX, LXXX and LXXXVII, processes for preparing them, compositions containing them and methods of using them
GB0314129D0 (en) 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
KR20070092994A (ko) 2003-06-18 2007-09-14 테바 파마슈티컬 인더스트리즈 리미티드 플루바스타틴 나트륨 결정형 ｘｉｖ, ｌｘｘｉｉｉ,ｌｘｘｉｘ, ｌｘｘｘ 및 ｌｘｘｘｖｉｉ, 이의 제조 방법,이를 포함하는 조성물 및 이를 사용하는 방법
EP1612212A1 (fr) 2003-07-03 2006-01-04 Teva Pharmaceutical Industries Ltd Formes cristallines d'acide zoledronique et de ses sels de sodium, sel de sodium de preparation de ceux-ci
EP1601658A1 (fr) 2003-11-24 2005-12-07 Teva Pharmaceutical Industries Limited Sels d'ammonium cristallins de la rosuvastatine
KR20060111675A (ko) 2003-12-16 2006-10-27 테바 파마슈티컬 인더스트리즈 리미티드 테가세로드 염기 및 그것의 염의 다형태
CA2550726A1 (fr) 2003-12-16 2005-06-30 Teva Pharmaceutical Industries Ltd. Procedes de preparation de formes cristallines d'aripiprazole
WO2005061493A2 (fr) 2003-12-18 2005-07-07 Teva Pharmaceutical Industries Ltd. Forme polymorphe b2 de base de ziprasidone
US20050187244A1 (en) 2004-01-30 2005-08-25 Entire Interest. Montelukast sodium polymorphs
EP1708708A1 (fr) 2004-01-30 2006-10-11 Teva Pharmaceutical Industries Ltd. Polymorphes d'acide sans montelukast
WO2005077941A2 (fr) 2004-02-11 2005-08-25 Teva Pharmaceutical Industries Ltd. Polymorphes de candesartan cilexetil
JPWO2005108370A1 (ja) 2004-04-16 2008-03-21 味の素株式会社 ベンゼン化合物
US20050256163A1 (en) 2004-04-26 2005-11-17 Ilan Kor Crystalline forms of fexofenadine hydrochloride and processes for their preparation
KR20070009726A (ko) 2004-05-07 2007-01-18 테바 파마슈티컬 인더스트리즈 리미티드 나테글리나이드의 다형태
US7473780B2 (en) 2004-05-18 2009-01-06 Teva Pharmeceutical Industries Ltd. Drying process for preparing crystalline solid famciclovir
TWI317731B (en) 2004-05-20 2009-12-01 Teva Pharm Fine Chemicals Srl Levalbuterol hydrochloride polymorph a
WO2006002348A2 (fr) 2004-06-23 2006-01-05 Teva Pharmaceutical Industies Ltd. Acide ibandronique solide et cristalline
EP2174935A1 (fr) 2004-06-29 2010-04-14 Teva Pharmaceutical Industries Ltd Compositions de linézolide
MX2007000093A (es) 2004-07-01 2007-06-14 Teva Pharma Formas cristalinas de 1,24(s)-dihidroxi vitamina d2.
US20060069150A1 (en) 2004-07-20 2006-03-30 Sandor Molnar Processes for preparation of crystalline mycophenolate sodium
CA2568629A1 (fr) 2004-07-22 2006-02-23 Teva Pharmaceutical Fine Chemicals S.R.L. Polymorphes du chlorhydrate d'atomoxetine
ES2262459T1 (es) 2004-07-22 2006-12-01 Teva Pharmaceutical Industries Ltd Nuevas formas cristalinas de atorvastatina semicalcica y procedimientos para su preparacion.
EP1713489B1 (fr) 2004-08-23 2011-01-19 Teva Pharmaceutical Industries Ltd Forme cristalline de sodium d'ibandronate et ses procedes de preparation
EP1704152A2 (fr) 2004-09-21 2006-09-27 Teva Pharmaceutical Industries Ltd Hydrobromure cristallin de clopidogrel et ses procedes de preparation
JP2008514641A (ja) 2004-09-28 2008-05-08 テバ ファーマシューティカル インダストリーズ リミティド 結晶形フェキソフェナジン、およびその調製方法
TW200630348A (en) 2004-11-02 2006-09-01 Teva Pharma Tadalafil crystal forms and processes for preparing them
JP2008516001A (ja) 2004-11-03 2008-05-15 テバ ファーマシューティカル インダストリーズ リミティド 非晶質、および多形のフォームのテルミサルタン・ナトリウム
EP1812428A2 (fr) 2004-11-19 2007-08-01 Teva Pharmaceutical Industries Ltd Formes cristallines de zolmitriptan
JP2007526251A (ja) 2004-12-03 2007-09-13 テバ ファーマシューティカル インダストリーズ リミティド エゼチミベ多形体
CA2591666A1 (fr) 2005-01-11 2006-07-20 Teva Pharmaceutical Fine Chemicals S.R.L. Procede de preparation du chlorhydrate 1-amino-3,5-dimethyladamantane
WO2006081515A2 (fr) 2005-01-27 2006-08-03 Teva Pharmaceutical Industries Ltd. Polymorphes d'hydrochlorure de duloxetine
WO2006084210A2 (fr) 2005-02-04 2006-08-10 Regents Of The University Of California, San Diego Composes modulant le hif et methodes d'utilisation associees
CN101128420A (zh) 2005-02-24 2008-02-20 泰华制药工业有限公司 拉多斯迪戈酒石酸盐结晶体、其制备方法及其药物组合物
EP1866295A2 (fr) 2005-02-24 2007-12-19 Teva Pharmaceutical Industries Ltd Procedes de preparation d'intermediaire linezolid
EP1856087A1 (fr) 2005-03-08 2007-11-21 Teva Pharmaceutical Industries Limited Formes cristallines de dnt-oxalaldehyde et procedes permettant de produire des formes cristallines de dnt-oxalaldehyde
EP1858891A2 (fr) 2005-03-14 2007-11-28 Teva Pharmaceutical Industries Ltd. Formes cristallines de mesylate de ziprasidone
EP1866275A1 (fr) 2005-04-06 2007-12-19 Teva Pharmaceutical Industries Ltd. Formes cristallines de pregabaline
DE102005019712A1 (de) 2005-04-28 2006-11-09 Bayer Healthcare Ag Dipyridyl-dihydropyrazolone und ihre Verwendung
MX2007014782A (es) 2005-05-23 2008-02-19 Novartis Ag Formas cristalinas y otras formas de las sales de acido lactico de 4-amino-5-fluoro-3-[6-(4-metilpiperazin-1-il)-1h-bencimidazol-2 -il]-1h quinolin-2-ona.
US7851000B2 (en) 2005-05-23 2010-12-14 Cadbury Adams Usa Llc Taste potentiator compositions and edible confectionery and chewing gum products containing same
CA2605736A1 (fr) 2005-05-23 2006-11-30 Teva Pharmaceutical Industries Ltd. Purification de cinacalcet
US20060276477A1 (en) 2005-06-06 2006-12-07 Fibrogen, Inc. Treatment method for anemia
EP1781611A1 (fr) 2005-06-09 2007-05-09 Teva Pharmaceutical Industries Ltd. Formes cristallines du carvedilol et leurs procedes de preparation
EP1893559A2 (fr) 2005-06-09 2008-03-05 Teva Pharmaceutical Industries Ltd Procede de preparation de la forme i de chlorhydrate de sertraline
AU2006259352A1 (en) 2005-06-15 2006-12-28 Fibrogen, Inc. Use of HIF 1alfa modulators for treatment of cancer
BRPI0605901A (pt) 2005-06-22 2007-12-18 Teva Pharma formas polimórficas de maleato de tegaserode
WO2007033216A2 (fr) 2005-09-12 2007-03-22 Beth Israel Deaconess Medical Center Procedes et compositions pour le traitement et le diagnostic de maladies caracterisees par la fuite vasculaire, l'hypotension, ou un etat procoagulant
WO2007038571A2 (fr) 2005-09-26 2007-04-05 Smithkline Beecham Corporation Antagonistes de la prolyl-hydroxylase
US20070088082A1 (en) 2005-09-28 2007-04-19 Judith Aronhime Polymorphic forms of ladostigil tartrate
US20090176726A1 (en) 2005-10-11 2009-07-09 Fisher David E Methods for treating mitf-related disorders
US7884208B2 (en) 2005-10-19 2011-02-08 Teva Pharmaceutical Industries, Ltd. Crystals of laquinimod sodium, and process for the manufacture thereof
WO2007053724A2 (fr) 2005-10-31 2007-05-10 Teva Pharmaceutical Industries Ltd. Formes cristallines d'un sel de potassium de cefdinir
WO2007053722A2 (fr) 2005-10-31 2007-05-10 Teva Pharmaceutical Industries Ltd. Formes cristalline du sel de cesium de cefdinir
WO2007059307A2 (fr) 2005-11-15 2007-05-24 Teva Pharmaceutical Industries Ltd. Formes amorphes et cristallines de telithromycine
US7563930B2 (en) 2005-11-22 2009-07-21 Teva Pharmaceutical Industries Ltd Crystal forms of Cinacalcet HCI and processes for their preparation
JP5202327B2 (ja) 2005-12-09 2013-06-05 アムジエン・インコーポレーテツド プロリルヒドロキシラーゼ阻害活性を示すキノロンベースの化合物、およびこの組成物、およびこの使用
TW200745026A (en) 2005-12-13 2007-12-16 Teva Pharma Crystal form of atorvastatin hemi-calcium and processes for preparation thereof
US7851476B2 (en) 2005-12-14 2010-12-14 Bristol-Myers Squibb Company Crystalline forms of 1-benzoyl-4-[2-[4-methoxy-7-(3-methyl-1H-1,2,4-triazol-1-YL)-1-[(phosphonooxy)methyl]-1H-pyrrolo[2,3-C]pyridin-3-YL]-1,2-dioxoethyl]-piperazine
WO2007081890A2 (fr) 2006-01-05 2007-07-19 Teva Gyógyszergyár Zártkörüen Müködö Részvénytársaság Production du dolasetron
GB2453819A (en) 2006-01-09 2009-04-22 Btg Int Ltd Modulators of hypoxia inducible factor-1 and related uses
WO2007082899A1 (fr) 2006-01-17 2007-07-26 Vib Vzw Inhibiteurs de la prolyl-hydroxylase 1 pour le traitement de la degenerescence des muscles du squelette
US20070225507A1 (en) 2006-01-18 2007-09-27 Gustavo Frenkel Process for preparing a crystalline form of Tegaserod maleate
JP4801451B2 (ja) 2006-01-19 2011-10-26 株式会社日立ハイテクノロジーズ 走査電子顕微鏡等に用いる電子銃の制御装置及び制御方法
US20070208053A1 (en) 2006-01-19 2007-09-06 Arnold Lee D Fused heterobicyclic kinase inhibitors
ITMI20060179A1 (it) 2006-02-02 2007-08-03 Abiogen Pharma Spa Procedimento per la risoluzione di miscele racemiche e complesso diastereoisomerico di un agente risolvente e di unantiomero di interesse
US20070293702A1 (en) 2006-02-21 2007-12-20 Viviana Braude Novel crystalline forms of armodafinil and preparation thereof
DE07752084T1 (de) 2006-02-27 2008-06-05 Teva Pharmaceutical Industries Ltd. Neuartige formen von fluvastatin-natrium und herstellung davon
AR059733A1 (es) 2006-03-07 2008-04-23 Smithkline Beecham Corp Compuesto derivado de glicina n- sustituida con heteroaromaticos bicicicos, composicion farmaceutica que lo comprende, uso para preparar un medicamento para tratar la anemia y proceso para su preparacion
US7588924B2 (en) 2006-03-07 2009-09-15 Procter & Gamble Company Crystal of hypoxia inducible factor 1 alpha prolyl hydroxylase
US20080027223A1 (en) 2006-03-23 2008-01-31 Teva Pharmaceutical Industries Ltd. Polymorphs of eszopiclone malate
WO2007136990A2 (fr) 2006-05-16 2007-11-29 Smithkline Beecham Corporation Inhibiteurs de prolyl hydroxylase
US20070293575A1 (en) 2006-06-15 2007-12-20 Fibrogen, Inc. Compounds and methods for treatment of cancer-related anemia
JO2934B1 (en) 2006-06-23 2015-09-15 سميث كلاين بيتشام كوربوريشن Prolyl hydroxylase inhibitors
CL2008000065A1 (es) 2007-01-12 2008-09-22 Smithkline Beecham Corp Compuestos derivados de glicina n-sustituida, inhibidores de hif prolil hidroxilasas; su proceso de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de la anemia.
TW200845991A (en) 2007-01-12 2008-12-01 Smithkline Beecham Corp N-substituted glycine derivatives: hydroxylase inhibitors
CA2683758A1 (fr) 2007-04-18 2008-10-30 Merck & Co., Inc. Nouveaux composes de type 1,8-naphthyridine
EP2155680B1 (fr) 2007-04-18 2013-12-04 Amgen, Inc Dérivés d'indanone qui inhibent la prolyle hydroxylase
ES2389063T3 (es) 2007-05-04 2012-10-22 Amgen, Inc Derivados de tienopiridina y tiazolopiridina que inhiben la actividad prolil hidroxilasa
EP2160187B1 (fr) 2007-05-16 2013-05-22 Merck Sharp & Dohme Corp. Spiroindalones
TW200908984A (en) 2007-08-07 2009-03-01 Piramal Life Sciences Ltd Pyridyl derivatives, their preparation and use
CA2696725A1 (fr) 2007-08-10 2009-03-26 Crystalgenomics, Inc. Derives de pyridine et leurs procedes d'utilisation
WO2009039321A1 (fr) 2007-09-19 2009-03-26 Smithkline Beecham Corporation Inhibiteurs de la prolyl hydroxylase
WO2009039323A1 (fr) 2007-09-19 2009-03-26 Smithkline Beecham Corporation Inhibiteurs de la prolyl hydroxylase
WO2009043093A1 (fr) 2007-10-04 2009-04-09 Newsouth Innovations Pty Limited Inhibition de hif
WO2009049112A1 (fr) 2007-10-10 2009-04-16 Smithkline Beecham Corporation Inhibiteurs de la prolyl hydroxylase
US8158762B2 (en) 2007-11-08 2012-04-17 Genentech, Inc. Anti-factor B antibodies and their uses
WO2009067790A1 (fr) 2007-11-26 2009-06-04 Uti Limited Partnership STIMULATION DU FACTEUR 1α INDUCTIBLE PAR L'HYPOXIE (HIF-1α) POUR LE TRAITEMENT DE LA MALADIE ASSOCIÉE À CLOSTRIDIUM DIFFICILE (MACD), POUR LA MOTILITÉ INTESTINALE ET POUR DÉTECTER UNE INFECTION
WO2009070644A1 (fr) 2007-11-30 2009-06-04 Smithkline Beecham Corporation Inhibiteurs de prolyl hydroxylases
US20100305133A1 (en) 2007-11-30 2010-12-02 Smithkline Beecham Corporation Prolyl Hydroxylase Inhibitors
US8269008B2 (en) 2007-12-03 2012-09-18 Fibrogen, Inc. Oxazolopyridine and isoxazolopyridine derivatives for use in the treatment of HIF-mediated conditions
WO2009086044A1 (fr) 2007-12-19 2009-07-09 Smith Kline Beecham Corporation Inhibiteurs de prolylhydroxylase
WO2009086592A1 (fr) 2008-01-04 2009-07-16 Garvan Institute Of Medical Research Procédé d'augmentation du métabolisme
EP2252619B1 (fr) 2008-01-11 2013-10-09 Fibrogen, Inc. Dérivés d'isothiazole-pyridine en tant que modulateurs de l'activité du hif (facteur inductible par l'hypoxie)
AR071997A1 (es) 2008-06-04 2010-07-28 Bristol Myers Squibb Co Forma cristalina de 6-((4s)-2-metil-4-(2-naftil)-1,2,3,4-tetrahidroisoquinolin-7-il)piridazin-3-amina
EP2717870B1 (fr) 2011-06-06 2017-09-27 Akebia Therapeutics Inc. Composition pour la stabilisation du facteur-2 alpha inductible par l'hypoxie utile pour le traitement du cancer
US9206134B2 (en) 2011-07-22 2015-12-08 Beijing Betta Pharmaceuticals Co. Ltd. Polymorphic forms of compounds as prolyl hydroxylase inhibitor, and uses thereof
US8772895B2 (en) 2011-11-28 2014-07-08 Taiwan Semiconductor Manufacturing Company, Ltd. Dark current reduction for back side illuminated image sensor
EP2637274B1 (fr) 2012-03-05 2022-05-04 Vetco Gray Scandinavia AS Agencement de terminaison de câble électrique
SG10201910773VA (en) 2013-06-13 2020-01-30 Akebia Therapeutics Inc Compositions and methods for treating anemia
AR099354A1 (es) 2013-11-15 2016-07-20 Akebia Therapeutics Inc Formas sólidas de ácido {[5-(3-clorofenil)-3-hidroxipiridin-2-carbonil]amino}acético, composiciones, y sus usos
WO2015112831A1 (fr) 2014-01-23 2015-07-30 Akebia Therapeutics, Inc. Compositions et méthodes de traitement de maladies oculaires
AU2016209126A1 (en) 2015-01-23 2017-08-10 Akebia Therapeutics, Inc. Solid forms of 2-(5-(3-fluorophenyl)-3-hydroxypicolinamido)acetic acid, compositions, and uses thereof
US20180065933A1 (en) 2015-03-20 2018-03-08 Akebia Therapeutics, Inc. Deuterium-enriched hypoxia-inducible factor prolyl hydroxylase enzyme inhibitors
US11324734B2 (en) 2015-04-01 2022-05-10 Akebia Therapeutics, Inc. Compositions and methods for treating anemia
MX2019006883A (es) 2016-12-13 2019-10-21 Crystal Pharmaceutical Suzhou Co Ltd Formas cristalinas novedosas de ácido {[5-(3-clorofenil)-3-idroxip iridina-2-carbonilo] amino} acético y procedimientos para la preparación del mismo.
EP3790863A1 (fr) 2018-05-09 2021-03-17 Akebia Therapeutics Inc. Procédé de préparation d'acide 2-[[5-(3-chlorophényl)-3-hydroxypyridine-2-carbonyl] amino]acétique
WO2021087144A1 (fr) 2019-10-31 2021-05-06 Akebia Therapeutics, Inc. Méthodes thérapeutiques à l'aide de vadadustat
US11524939B2 (en) 2019-11-13 2022-12-13 Akebia Therapeutics, Inc. Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130203816A1 (en) * 2006-06-26 2013-08-08 Akebia Therapeutics Inc. Prolyl hydroxylase inhibitors and methods of use
US20120309977A1 (en) * 2011-06-06 2012-12-06 Akebia Therapeutics Inc. Process for preparing [(3-hydroxypyridine-2-carbonyl)amino]alkanoic acids, esters and amides

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
Bernstein ACA Transactions 2004, 39, 14-23. *
Braga, Grepioni Chem. Commun. 20115, 3635-3645. *
BYRN ET AL.: "PHARMACEUTICAL SOLIDS: A STRATEGIC APPROACH TO REGULATORY CONSIDERATIONS", PHARMACEUTICAL RESEARCH, vol. 12, no. 7, 1 July 1995 (1995-07-01), pages 945 - 954, XP000996386, ISSN: 0724-8741, DOI: 10.1023/A:1016241927429 *
Jones et al. MRS Bulletin 2006, 31, 875-879. *
Price Advanced Drug Delivery Reviews 2004, 56, 301-319. *
See also references of WO2015073779A1 *
SEYMOUR ET AL.: "Decision T 0777/08 of the Boards of Appeal of the European Patent Office", 8 July 2011 (2011-07-08), pages 1-3 and 1 - 14, XP055351363, Retrieved from the Internet <URL:http://www.epo.org/law-practice/case-law-appeals/pdf/t080777ex1.pdf> [retrieved on 20170303] *
Unidentified author, unidentified source, unidentified date: "8.3.2 Generation of Form II and In-Situ Conversion to Form I", page 20; designated by the applicant as "experimental report concerning forms A and C". *

Also Published As

Publication number Publication date
TW201946625A (zh) 2019-12-16
JP2020183408A (ja) 2020-11-12
AU2014348523A1 (en) 2016-06-09
JP2019167353A (ja) 2019-10-03
EP3068394A1 (fr) 2016-09-21
TW202126300A (zh) 2021-07-16
BR112016011065A2 (pt) 2017-08-08
JP2025011163A (ja) 2025-01-23
CA2930128A1 (fr) 2015-05-21
WO2015073779A1 (fr) 2015-05-21
DOP2016000109A (es) 2016-08-31
US20190290624A1 (en) 2019-09-26
CR20200220A (es) 2020-11-18
CN114890943A (zh) 2022-08-12
IL281648A (en) 2021-05-31
US12419877B2 (en) 2025-09-23
US11690836B2 (en) 2023-07-04
MX2021007268A (es) 2021-07-15
TW201605801A (zh) 2016-02-16
AU2020294308A1 (en) 2021-02-18
US10596158B2 (en) 2020-03-24
TWI902264B (zh) 2025-10-21
JP2022176961A (ja) 2022-11-30
SA516371129B1 (ar) 2019-07-28
RU2016123382A (ru) 2017-12-20
EP3578546A1 (fr) 2019-12-11
US20170258773A1 (en) 2017-09-14
CN105916502A (zh) 2016-08-31
NZ759132A (en) 2022-03-25
US9701636B2 (en) 2017-07-11
ZA201905255B (en) 2020-11-25
AR128483A2 (es) 2024-05-15
TW202335670A (zh) 2023-09-16
ZA202004764B (en) 2025-10-29
BR112016011065A8 (pt) 2020-04-22
AU2014348523B2 (en) 2019-01-03
TW202435877A (zh) 2024-09-16
KR20160083118A (ko) 2016-07-11
MX2021001169A (es) 2023-02-10
KR102381295B1 (ko) 2022-03-31
NZ719970A (en) 2022-03-25
PE20160945A1 (es) 2016-09-26
PH12021551124A1 (en) 2024-04-29
PH12016500866A1 (en) 2016-06-20
TWI665190B (zh) 2019-07-11
SG10201803862UA (en) 2018-06-28
TWI846166B (zh) 2024-06-21
AU2022259767B2 (en) 2024-08-15
CR20160222U (es) 2016-08-26
US9987262B2 (en) 2018-06-05
MX383715B (es) 2025-03-14
JP2016537365A (ja) 2016-12-01
SG10202012791TA (en) 2021-01-28
KR102495018B1 (ko) 2023-02-06
ZA201603189B (en) 2019-11-27
MY180626A (en) 2020-12-03
IL245634A0 (en) 2016-06-30
BR112016011065B1 (pt) 2022-10-25
US20180280365A1 (en) 2018-10-04
AU2020294308B2 (en) 2022-08-11
RU2021125455A (ru) 2021-10-05
CL2016001150A1 (es) 2016-12-09
MA39033A1 (fr) 2017-11-30
US11065237B2 (en) 2021-07-20
AU2022259767A1 (en) 2022-12-01
AU2019202144B2 (en) 2020-10-08
AU2019202144A1 (en) 2019-04-18
AR099354A1 (es) 2016-07-20
TWI788702B (zh) 2023-01-01
KR20220042498A (ko) 2022-04-05
US20220040159A1 (en) 2022-02-10
US20150141467A1 (en) 2015-05-21
MX2016006271A (es) 2017-05-04
US10149842B2 (en) 2018-12-11
US20200345711A1 (en) 2020-11-05
US20240122910A1 (en) 2024-04-18

Similar Documents

Publication Publication Date Title
IL281648A (en) Solid forms of }[5-(3-chlorophenyl)-3-hydroxypyridi-2-carbonyl]amino{ acetic acid, their compositions and uses
HUE038664T2 (hu) Hialuronsav C6-C18-acilezett származéka, eljárás annak elõállítására, erre épülõ nanomicelláris kompozíció, eljárás annak elõállítására és eljárás stabilizált nanomicelláris kompozíció elõállítására, valamint annak alkalmazása
EP2947084B8 (fr) Composé hétérocyclique à cinq et six chaînons, procédé de préparation, composition pharmaceutique et application associés
IL224288A (en) Derivatives of converted pyrazolamide, pharmaceutical preparations containing them and their use
WO2012058211A3 (fr) Dérivés quinazoline, compositions et utilisations correspondantes
EP3054892A4 (fr) Compositions à base de cire, objets fabriqués à partir de celles-ci et procédés de fabrication et d&#39;utilisation
PL3060195T3 (pl) Kompozycja kosmetyczna na bazie kwasu hialuronowego, sposób jej wytwarzania oraz jej zastosowanie
EP3060041A4 (fr) Composés de prostacycline, compositions en contenant et leurs procédés d&#39;utilisation
EP3082819A4 (fr) Composés substitués de diaminopyrimidyle, compositions à base de ceux-ci, et méthodes de traitement les utilisant
EP3021843A4 (fr) Composés anti-viraux, compositions pharmaceutiques et méthodes d&#39;utilisation correspondantes
EP3054929A4 (fr) Formulations mucoadhésives à libération contrôlée de lévodopa et/ou d&#39;esters de lévodopa et leurs utilisations
EP3247355A4 (fr) Formes solides d&#39;acide 2-(5-(3-fluorophényl)-3-hydroxypicolinamido)acétique, compositions et utilisation dudit acide
EP3039131A4 (fr) Composition d&#39;enzyme et utilisations de celle-ci
EP2852588B8 (fr) Dérivés d&#39;hydantoïne en tant qu&#39;inhibiteurs de kv3
EP3020391A4 (fr) Composition cosmétique fonctionnelle comprenant des facteurs de croissance et des acides aminés
EP3049389A4 (fr) Inhibiteurs de kynurénine-3-monooxygénase, compositions pharmaceutiques et procédés d&#39;utilisation de ceux-ci
EP3057596A4 (fr) Compositions et procédés pour les administrer
EP3049077A4 (fr) Inhibiteurs de kynurénine-3-monooxygénase, compositions pharmaceutiques et procédés d&#39;utilisation de ces compositions
EP3022186A4 (fr) Dérivés de la quinazoline, compositions correspondantes et leur utilisation en tant qu&#39;agents pharmaceutiques
ZA201306905B (en) Novel octahydrothienoquinonline derivative,pharmaceutical composition comprising derivative, and use of these
IL234825A0 (en) Phenyl-urea and phenyl-carbamate derivatives as protein aggregation suppressors, preparations containing them and their uses
HK1212978A1 (zh) 芥子酸的新型衍生物
HK1223300A1 (zh) 皮质类固醇组合物
EP3086779A4 (fr) Formulations de dépôt à libération prolongée de protéines thérapeutiques, et utilisations correspondantes
HK1216721A1 (zh) 治疗肝脏疾病或病状的用途和方法

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20160603

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

RIN1 Information on inventor provided before grant (corrected)

Inventor name: LUONG, ANNE

Inventor name: COPP, JAMES DENSMORE

Inventor name: NEWMAN, ANN W.

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20170324

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/44 20060101ALI20170320BHEP

Ipc: C07D 213/65 20060101AFI20170320BHEP

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1227294

Country of ref document: HK

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20180418

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: AKEBIA THERAPEUTICS, INC.

18W Application withdrawn

Effective date: 20190516

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1227294

Country of ref document: HK